Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines

  title={Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines},
  author={Huub F J Savelkoul and Valerie A. Ferro and Marius M. Strioga and Virgil E. J. C. Schijns and Diane Medved Harper},
The existence of pathogens that escape recognition by specific vaccines, the need to improve existing vaccines and the increased availability of therapeutic (non-infectious disease) vaccines necessitate the rational development of novel vaccine concepts based on the induction of protective cell-mediated immune responses. For naive T-cell activation, several signals resulting from innate and adaptive interactions need to be integrated, and adjuvants may interfere with some or all of these… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 13 extracted citations

Towards the Application of Human Defensins as Antivirals

Biomolecules & therapeutics • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 121 references

Freeing vaccine adjuvants from dangerous immunological dogma.

Expert review of vaccines • 2008
View 7 Excerpts
Highly Influenced

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.

Proceedings of the National Academy of Sciences of the United States of America • 2009
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…